Loading quotes...
Forecast
There is no analyst data available for this company.
News Go to news feed
Terumo posts record revenue of 1.1 trillion yen in fiscal 2025
In the fiscal year 2025, which ended in March 2026, Terumo posted its fifth consecutive record revenue at 1.1 trillion yen (+9%) and an operating income of 176.3 billion yen. Adjusted operating income was 219.4 billion yen; margins remained strong despite one-off charges in Q4. Management expects higher operating margins of 20%+ for 2026 and cites the removal of one-off charges, expansion of the neurovascular business and manufacturing optimizations as drivers for further profit growth. Risks include macroeconomic pressure, tariffs, supply-chain disruptions and raw material costs; the stock reacted with a slight decline of 0.41%. » More on de.investing.com
Terumo posts record revenue in Q3 FY2025 thanks to North America, shares fall
Terumo reported its highest quarterly revenue in company history for Q3 FY2025 of JPY 2.966 billion (+13% y/y) and year-to-date revenue of JPY 8.316 billion (+8%). Adjusted operating profit for the first three quarters rose to JPY 1.735 billion (+9%) with a margin of 20.9%, while free cash flow plunged to JPY -1.738 billion. Growth drivers were North America and the Cardiac and Vascular (notably TIS) and Blood and Cell Technologies segments; the acquisition of OrganOx made a significant contribution. Despite the strong figures, the stock fell 2.87%âinvestors are concerned about ongoing tariffs, inflationary pressure and the sustainability of price measures. » More on de.investing.com
Terumo posts record revenue and strong profit growth in Q2 FY2025
Terumo reported record revenue of „534.9 billion (+5%) for the first half and marked profit growth: operating income „101.0 billion (+15%), adjusted operating income „114.4 billion (+10%) and net profit „76.9 billion (+22%). The drivers were mainly strong sales in North America, notably the Cardiac and Vascular segment; management cited price measures and cost control as margin supports. Free cash flow fell 50% to „31.0 billion due to higher investments and the acquisition of OrganOx, while guidance for revenue and adjusted operating income was raised. The stock dipped slightly after earnings per share narrowly missed expectations („23.76 vs. „24.07). » More on de.investing.com
Historical dividends Dividends
All dividend metrics All metricsFinancials
| (EUR) | Jun 2026 | |
|---|---|---|
| Revenue | 1.68b | 9,53% |
| Gross profit | 961.85m | 12,08% |
| Net profit | 379.41m | 53,70% |
| EBITDA | 517.34m | 12,51% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | 20.34b⏠|
Number of shares | 1.48b |
52-week high/low | 14,59⏠- 10,24⏠|
Dividend yield | 1,18% |
Dividends TTM | 0,16⏠|
Beta | 0,23 |
P/E ratio | 22,96 |
PEG ratio | 0,72 |
P/B ratio | 2,27 |
P/S ratio | 3,19 |
Company profile
Die Terumo Corporation beschĂ€ftigt sich mit der Herstellung und dem Verkauf von medizinischen Produkten und GerĂ€ten weltweit. Das Unternehmen ist in drei Segmenten tĂ€tig: Cardiac and Vascular Company, Medical Care Solutions Company, und Blood and Cell Technologies Company. Das Segment Cardiac and Vascular Company bietet angiografische FĂŒhrungsdrĂ€hte, angiografische Katheter, EinfĂŒhrschleusen, GefĂ€ĂverschlussgerĂ€te, PTCA-Ballonkatheter, Koronarstents, selbstexpandierende periphere Stents, intravaskulĂ€re Ultraschallsysteme, Bildgebungskatheter und andere an; Coils, Stents und intrasakkulĂ€re GerĂ€te fĂŒr die Behandlung von zerebralen Aneurysmen; Embolisationssysteme, Aspirationskatheter und Gerinnselentferner fĂŒr die Behandlung von ischĂ€mischen SchlaganfĂ€llen und andere; Oxygenatoren, kardio-pulmonale Bypass-Systeme und andere; sowie kĂŒnstliche GefĂ€Ă- und Stentgrafts. Das Segment Medical Care Solutions Company bietet Spritzen, Infusionspumpen, Spritzenpumpen, Infusionsleitungen, intravenöse Lösungen, FlĂŒssigkeiten fĂŒr die Peritonealdialyse, Produkte fĂŒr die Schmerzbehandlung und nahrhafte Lebensmittel, AdhĂ€sionsbarrieren und andere; Blutzuckermesssysteme, Einwegnadeln fĂŒr Pen-Injektoren, Insulinpflasterpumpen, BlutdruckmessgerĂ€te, digitale Thermometer und andere; und die Auftragsfertigung von vorgefĂŒllten Spritzen, GerĂ€ten fĂŒr Pharmaunternehmen zur Verwendung in ArzneimittelsĂ€tzen, wie vorfĂŒllbare Spritzen, Nadeln fĂŒr das pharmazeutische VerpackungsgeschĂ€ft und andere. Das Segment Blood and Cell Technologies Company bietet Blutbeutel, Komponentenentnahmesysteme, automatisierte Blutverarbeitungssysteme, Systeme zur Reduzierung von Krankheitserregern, Zentrifugal-Apherese-Systeme, Zellexpansionssysteme und andere an. Das Unternehmen war frĂŒher unter dem Namen Sekisen Ken-onki Corporation bekannt und Ă€nderte im Oktober 1974 seinen Namen in Terumo Corporation. Die Terumo Corporation wurde 1921 gegrĂŒndet und hat ihren Hauptsitz in Tokio, Japan.
| Name | Terumo |
| CEO | Hikaru Samejima |
| Headquarters | Tokyo,
ty Japan |
| Website | |
| Sector | Health Care |
| Industry | Health Care Equipment & Supplies |
| IPO | 01/04/2000 |
| Employees | 31.185 |
Deep Dive
Ticker symbols
| Exchange | Symbol |
|---|---|
Pnk | TRUMF |
Japan Exchange Group | 4543.T |
Frankfurt | TUO.F |
DĂŒsseldorf | TUO.DU |
MĂŒnchen | TUO.MU |
Discover assets
Shareholders of Terumo also invest in the following assets
